Cytochrome P450 Degradation and Its Clinical Relevance

Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad

Volumn , Issue , 2010, Pages 363-406

  Liao, Mingxiang ^a   Kang, Ping ^b   Murray, Bernard P ^c   Correia, Maria Almira ^d  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b PFIZER INC   (United States)

^c Gilead Sciences   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytochrome P450 degradation and clinical relevance; P450 degradation pathological relevance in autoimmune hepatitis and drug induced hepatitis; Pharmacokinetic drug interactions and P450 turnover and drug interactions

Indexed keywords

EID: 84884445011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470538951.ch11     Document Type: Chapter

References (231)

1. Abu-Bakar A, Lämsä V, Arpiainen S, Moore MR, Lang MA, Hakkola J. Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2. Drug Metab Dispos 2007; 35: 787-794.
2. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8 (4 Suppl):S 49-S 54.
3. Aguiar M, Masse R, Gibbs BF. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev 2005; 37: 379-404.
4. Aitken AE, Lee CM, Morgan ET. Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med 2008; 44: 1161-1168.
5. Arnason TG, Pisclevich MG, Dash MD, Davies GF, Harkness TA. Novel interaction between Apc5p and Rsp5p in an intracellular signaling pathway in Saccharomyces cerevisiae. Eukaryot Cell 2005; 4: 134-146.
6. Bachmair A, Varshavsky A. The degradation signal in a short-lived protein. Cell 1989; 56: 1019-1032.
7. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-110.
8. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005; 67: 435-443.
9. Banerjee A, Kocarek TA, Novak RF. Identification of a ubiquitination target/ substrate-interaction domain of cytochrome P-450 (CYP) 2E1. Drug Metab Dispos 2000; 28: 118-124.
10. Bardag-Gorce F, Li J, French BA, French SW. Ethanol withdrawal induced CYP2e1 degradation in vivo blocked by proteasome inhibitor PS-341. Free Radic Biol Med 2002; 32: 17-21.
11. Barmada S, Kienle E, Koop DR. Rabbit P450 2E1 expressed in CHO-K1 cells has a short half-life. Biochem Biophys Res Commun 1995; 206: 601-607.
12. Bays NW, Gardner RG, Seelig LP, Joazeiro CA, Hampton RY. Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat Cell Biol 2001a; 3: 24-29.
13. Bays NW, Wilhovsky SK, Goradia A, Hodgkiss-Harlow K, Hampton RY. HRD4/ NPL4 is required for the proteasomal processing of ubiquitinated ER proteins. Mol Biol Cell 2001b; 12: 4114-4128.
14. Bazirgan OA, Hampton RY. Cdc48-Ufd2-Rad23: the road less ubiquitinated? Nat Cell Biol 2005; 7: 207-209.
15. Belgareh-Touzé N, Léon S, Erpapazoglou Z, Stawiecka-Mirota M, Urban-Grimal D, Haguenauer-Tsapis R. Versatile role of the yeast ubiquitin ligase Rsp5p in intracellular trafficking. Biochem Soc Trans 2008; 36: 791-796.
16. Belloc C, Gauffre A, André C, Beaune PH. Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics 1997; 7: 181-186.
17. Berlin CM, Schimke RT. Influence of turnover rates on the responses of enzymes to cortisone. Mol Pharmacol 1965; 1: 149-156.
18. Bernassola F, Karin M, Ciechanover A, Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008; 14: 10-21.
19. Biederer T, Volkwein C, Sommer T. Role of Cue1p in ubiquitination and degradation at the ER surface. Science 1997; 278: 1806-1809.
20. Bolender R, Weibel E. A morphometric study of the removal of phenobarbital induced membranes from hepatocytes after cessation of treatment. J Cell Biol 1973; 56: 746-761.
21. Bonifacino JS, Lippincott-Schwartz J. Degradation of proteins within the endoplasmic reticulum. Curr Opin Cell Biol 1991; 3: 592-600.
22. Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem 2003; 72: 395-447.
23. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, Pohl LR. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol 1996; 9: 1159-1166.
24. Broccardo CJ, Billings RE, Chubb LS, Andersen ME, Hanneman WH. Single cell analysis of switch-like induction of CYP1A1 in liver cell lines. Toxicol Sci 2004; 78: 287-294.
25. Cairns W, Smith CA, McLaren AW, Wolf CR. Characterization of the human cytochrome P4502D6 promoter: A potential role for antagonistic interactions between members of the nuclear receptor family. J Biol Chem 1996; 271: 25269-25276.
26. Chang TK, Chen J, Lee WB. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 2001; 299: 874-882.
27. Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31: 1391-1397.
28. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 1995; 9: 1586-1597.
29. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25: 1165-1175.
30. Ciechanover A, Ben-Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol 2004; 14: 103-106.
31. Ciechanover A, Heller H, Elias S, Haas AL, Hershko A. ATP dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci USA 1980; 77: 1365-1368.
32. Correia MA. Cytochrome P450 turnover. Methods Enzymol 1991; 206: 315-325.
33. Correia MA. Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev 2003; 35: 107-143.
34. Correia MA. Human and rat liver cytochromes P450: functional markers, diagnostic inhibitor probes and parameters frequently used in P450 studies. In: Ortiz de Montellano P, editor. Cytochrome P450: Structure, Mechanism and Biochemistry. New York: Kluwer-Academic/Plenum Press, 2005, pp. 619-657.
35. Correia MA, Liao M. Cellular proteolytic systems in P450 degradation: evolutionary conservation from Saccharomyces cerevisiae to mammalian liver. Expert Opin Drug Metab Toxicol 2007; 3: 33-49.
36. Correia MA, Ortiz de Montellano PR. Inhibition of cytochrome P450 enzymes. In: Ortiz de Montellano, PR, editor. Cytochrome P-450. Structure, Mechanism, and Biochemistry. New York: Kluwer-Plenum Press, 2005, pp. 247-322.
37. Correia MA, Litman DA, McColl KEL, Schmid R, Thompson GC. Effect of cimetidine on phenobarbitone-induced changes in hepatic cytochrome P450 and d-aminolaevulinic acid synthase. Proc Br Pharmacol 1983;C 24.
38. Correia MA, Decker C, Sugiyama K, Caldera P, Bornheim L, Wrighton SA, Rettie AE, Trager WF. Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. Arch Biochem Biophys 1987; 258: 436-451.
39. Correia MA, Sugiyama K, Yao KQ. Degradation of rat hepatic cytochrome P-450p. Drug Metab Rev 1989; 20: 615-628.
40. Correia MA, Davoll SH, Wrighton SA, Thomas PE. Degradation of rat liver cytochromes P-450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: Characterization of the proteolytic system. Arch Biochem Biophys 1992; 297: 228-238.
41. Correia MA, Sadeghi S, Mundo-Paredes E. Cytochrome P450 ubiquitination: branding for the proteolytic slaughter? Annu Rev Pharmacol Toxicol 2005; 45: 439-464.
42. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem Biochem 1996; 65: 801-847.
43. Cuervo AM, Dice JF. Lysosomes, a meeting point of proteins, chaperones, and proteases. J Mol Med 1998; 76: 6-12.
44. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292-1295.
45. Cyr DM, Höhfeld J, Patterson C. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci 2002; 27: 368-375.
46. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001; 3: 740-744.
47. Dai Y, Cederbaum A. Inactivation and degradation of human cytochrome P4502E1 by CCl4 in a transfected HepG2 cell line. J Pharmacol Exp Ther 1995; 275: 1614-1622.
48. de Duve C, Gianetto R, Appelmans F, Wattiaux R. Enzymic content of the mitochondria fraction. Nature (London) 1953; 172: 1143-1144.
49. DeMartino GN, Moomaw CR, Zagnitko OP, Proske RJ, Chu-Ping M, Afendis SJ, Swaffield JC, Slaughter CA. PA700, an ATP-dependent activator of the 20 S proteasome, is an ATPase containing multiple members of a nucleotide-binding protein family. J Biol Chem 1994; 269: 20878-20884.
50. Deol P, Zaiss DM, Monaco JJ, Sijts AJ. Rates of processing determine the immunogenicity of immunoproteasome-generated epitopes. J Immunol 2007; 178: 7557-7562.
51. Dice JF. Molecular determinants of protein half-lives in eukaryotic cells. FASEB J 1987; 1: 349-357.
52. Dice JF, Terlecky SR, Chiang HL, Olson TS, Isenman LD, Short-Russell SR, Freundlieb S, Terlecky LJ. A selective pathway for degradation of cytosolic proteins by lysosomes. Semin Cell Biol 1990; 1: 449-455.
53. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 1996; 271: 7273-7276.
54. Doolman R, Leichner GS, Avner R, Roitelman J. Ubiquitin is conjugated by membrane ubiquitin ligase to three sites, including the N terminus, in transmembrane region of mammalian 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for sterol-regulated enzyme degradation. J Biol Chem 2004; 279: 38184-38193.
55. Dunlop RA, Rodgers KJ, Dean RT. Recent developments in the intracellular degradation of oxidized proteins. Free Radic Biol Med 2002; 33: 894-906.
56. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol 1996; 50: 573-582.
57. Eliasson E, Johansson I, Ingelman-Sundberg M. Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation. Proc Natl Acad Sci USA 1990; 87: 3225-3229.
58. Eliasson E, Mkrtchian S, Ingelman-Sundberg M. Hormone-and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem 1992; 267: 15765-15769.
59. Eliasson E, Mkrtchian S, Halpert JR, Ingelman-Sundberg M. Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1. J Biol Chem 1994; 269: 18378-18383.
60. Ernest CS 2nd, Hall SD, Jones DR. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exptl Ther 2005; 312: 583-591.
61. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
62. Faouzi S, Medzihradszky KF, Hefner C, Maher JJ, Correia MA. Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase P97? Biochemistry 2007; 46: 7793-7803.
63. Finley D. Ubiquitin chained and crosslinked. Nat Cell Biol 2002; 4 :E 121-E 123.
64. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-1059.
65. Freeman JE, Wolf CR. Evidence against a role for serine 129 in determining murine cytochrome P450 Cyp2E-1 protein levels. Biochemistry 1994; 33: 13963-13966.
66. Freemont PS. RING for destruction? Curr Biol 2000; 10 :R 84-R 87.
67. Gardner RG, Hampton RY. A " distributed degron " allows regulated entry into the ER degradation pathway. EMBO J 1999; 18: 5994-6004.
68. Gertz M, Davis JD, Harrison A, Houston JB, Galetin A. Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 2008; 9: 785-795.
69. Glickman MH, Ciechanover A. The ubiquitin-proteasome pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
70. Glickman MH, Rubin DM, Fried VA, Finley D. The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol Cell Biol 1998; 18: 3149-3162.
71. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349: 132-138.
72. Goasduff T, Cederbaum AI. NADP H-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species. Arch Biochem Biophys 1999; 370: 258-270.
73. Goasduff T, Cederbaum AI. CYP2E1 degradation by in vitro reconstituted systems: role of the molecular chaperone hsp90. Arch Biochem Biophys 2000; 379: 321-330.
74. Goldberg AL, St. John AC. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem 1976; 45: 747-803.
75. Goldberg AL. ATP-dependent proteases in prokaryotic and eukaryotic cells. Semin Cell Biol 1991; 1: 423-432.
76. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007; 35: 12-17.
77. Gooderham NJ, Mannering GJ. Depression of cytochrome P-450 and alterations of protein metabolism in mice treated with the interferon inducer polyriboinosinic acid: polyribocytidylic acid. Arch Biochem Biophys 1986; 250: 418-425.
78. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano P, editor. Cytochrome P450: Structure, Mechanism and Biochemistry. New York: Kluwer-Academic/Plenum Press, 2005, pp. 377-530.
79. Haas AL, Siepmann TJ. Pathways of ubiquitin conjugation. FASEB J 1997; 11: 1257-1268.
80. Haas AL, Murphy KE, Bright PM. The inactivation of ubiquitin accounts for the inability to demonstrate ATP, ubiquitin-dependent proteolysis in liver extracts. J Biol Chem 1985; 260: 4694-4703.
81. Hampton RY. ER-associated degradation in protein quality control and cellular regulation. Curr Opin Cell Biol 2002; 14: 476-482.
82. Hampton RY, Rine J. Regulated degradation of HMG-CoA reductase, an integral membrane protein of the endoplasmic reticulum, in yeast. J Cell Biol 1994; 125: 299-312.
83. Hampton RY, Gardner RG, Rine J. Role of 26S proteasome and HRD genes in the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein. Mol Biol Cell 1996; 7: 2029-2044.
84. Haynes CM, Caldwell S, Cooper AA. An HRD/DERindependent ER quality control mechanism involves Rsp5p-dependent ubiquitination and ER-Golgi transport. J Cell Biol 2002; 158: 91-101.
85. He K, He YA, Szklarz GD, Halpert JR, Correia MA. Secobarbital-mediated in activation of cytochrome P450 2B1 and its active site mutants: partitioning between heme and protein alkylation and epoxidation. J Biol Chem 1996; 271: 25864-25872.
86. He K, Bornheim LM, Falick AM, Maltby D, Yin H, Correia MA. Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. Biochemistry 1998; 37: 17448-17457.
87. Heink S, Ludwig D, Kloetzel P, Kruger E. IFN γ-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 2005; 102: 9241-9246.
88. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992; 61: 761-807.
89. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
90. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoh M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R and K383N found in a Japanese population. Drug Metab Dispos 2005; 233: 630-636.
91. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001; 2: 195-201.
92. Hochstrasser M, Varshavsky A. In vivo degradation of a transcriptional regulator: the yeast alpha 2 repressor. Cell 1990; 61: 697-708.
93. Hochstrasser M, Papa FR, Chen P, Swaminathan S, Johnson P, Stillman L, Americk AY, Li SY, et al. The DOA pathway: studies on the functions and mechanisms of ubiquitin-dependent protein degradation in the yeast Saccharomyces cerevisiae. Cold Spring Harb Symp Quant Biol 1995; 60: 503-513.
94. Hollenberg PF, Kent UM, Bumpus NN. Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 2008; 21: 189-205.
95. Huan JY, Koop DR. Tightly regulated and inducible expression of rabbit CYP2E1 using a tetracycline-controlled expression system. Drug Metab Dispos 1999; 27: 549-554.
96. Huan JY, Streicher JM, Bleyle LA, Koop DR. Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells. Toxicol Appl Pharmacol 2004; 199: 332-343.
97. Huyer G, Piluek WF, Fansler Z, Kreft SG, Hochstrasser M, Brodsky JL, Michaelis S. Distinct machinery is required in Saccharomyces cerevisiae for the endoplasmic reticulum-associated degradation of a multispanning membrane protein and a soluble luminal protein. J Biol Chem 2004; 279: 38369-38378.
98. Imaoka S, Obata N, Hiroi T, Osada-Oka M, Hara R, Nishiguchi S, Funae Y. A new epitope of CYP2D6 recognized by liver kidney microsomal autoantibody from japanese patients with autoimmune hepatitis. Biol Pharm Bull 2005; 28: 2240-2243.
99. Islam M, Frye RF, Richards TJ, Sbeitan I, Donnelly SS, Glue P, Agarwala SS, Kirkwood JM. Differential effect of IFN a-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8: 2480-2487.
100. Israel BC, Blouin RA, McIntyre W, Shedlofsky SI. Effects of interferon-a monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-235.
101. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, Reimann JD, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10: 429-439.
102. Jansson I, Curti M, Epstein PM, Peterson JA, Schenkman JB. Relationship between phosphorylation and cytochrome P450 destruction. Arch Biochem Biophys 1990; 283: 285-292.
103. Jin S, Yi F, Zhang F, Poklis JL, Li PL. Lysosomal targeting and trafficking of acid sphingomyelinase to lipid raft platforms in coronary endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 2056-2062.
104. Joazeiro CA, Weissman AM. RING finger proteins: mediators of ubiquitin ligase activity. Cell 2000; 102: 549-552.
105. Kabunga P, Coghlan G. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Drugs 2008; 68: 1635-1645.
106. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos 2008; 36: 490-499.
107. Kato M, Chiba K, Horikawa M, Sugiyama Y. The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 2005; 20: 236-243.
108. 193-212: a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-1489.
109. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology 2004; 101: 729-737.
110. Kim HT, Kim KP, Kisselev AF, Lledias F, Scaglione KM, Skowyra D, Gygi SP, Goldberg AL. Certain E2-E3 pairs synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 2007; 282: 17375-17386.
111. Kimzey AL, Weitz KK, Guengerich FP, Zangar RC. Hydroperoxy-10,12-octadecadienoic acid stimulates cytochrome P450 3A protein aggregation by a mechanism that is inhibited by substrate. Biochemistry 2003; 42: 12691-12699.
112. King RW, Glotzer M, Kirschner MW. Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates. Mol Biol Cell 1996; 7: 1343-1357.
113. Klionsky DJ. The molecular machinery of autophagy: unanswered questions. J Cell Sci 2005; 118: 7-18.
114. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8: 931-937.
115. Koenigs LL, Trager WF. Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 1998; 37: 10047-10061.
116. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M, Rushmore TH, Trager WF. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 1999; 38: 2312-2319.
117. Kopitz J, Kisen GO, Gordon PB, Bohley P, Seglen PO. Nonselective autophagy of cytosolic enzymes by isolated rat hepatocytes. J Cell Biol 1990; 111: 941-953.
118. Korsmeyer KK, Davoll S, Figueiredo-Pereira ME, Correia MA. Proteolytic degradation of heme-modified hepatic cytochromes P450: a role for phosphorylation, ubiquitination and the 26S proteasome? Arch Biochem Biophys 1999; 365: 31-44.
119. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, Bierman CW. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476-480.
120. Lecoeur S, André C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996; 50: 326-333.
121. Lee C, Kim B, Li L, Morgan ET. Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem 2008; 283: 889-898.
122. Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity. J Pharmacol Exp Ther 1992; 263: 360-367.
123. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996; 49: 234-243.
124. Liao M, Faouzi S, Karyakin A, Correia MA. Endoplasmic reticulum-associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: Further characterization of cellular participants and structural determinants. Mol Pharmacol 2006; 69: 1897-1904.
125. Liao M, Zgoda VG, Murray BP, Correia MA. Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: Further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins. Mol Pharmacol 2005; 67: 1460-1469.
126. Liiv I, Teesalu K, Peterson P, Clemente MG, Perheentupa J, Uibo R. Epitope mapping of cytochrome P450 cholesterol side-chain cleavage enzyme by sera from patients with autoimmune polyglandular syndrome type 1. Eur J Endocrinol 2002; 146: 113-119.
127. Lippincott-Schwartz J, Bonifacino JS, Yuan LC, Klausner RD. Degradation from the endoplasmic reticulum: disposing of newly synthesized proteins. Cell 1988; 54: 209-220.
128. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-774.
129. Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, Vergani D. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007; 46: 472-484.
130. Lord J, Davey J, Frigerio L, Roberts L. Endoplasmic reticulum-associated protein degradation. Semin Cell Dev Biol 2000; 11: 159-164.
131. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553.
132. Lu P, Zhou X, Shen M, Lu K. Function of WW domains as phosphoserine-or phosphothreonine-binding modules. Science 1999; 283: 1325-1328.
133. Ma Q. Aryl hydrocarbon receptor degradation-promoting factor (ADPF) and the control of the xenobiotic response. Mol Intervent 2007; 7: 133-137.
134. Ma Y, Thomas MG, Okamoto M, Bogdanos DP, Nagl S, Kerkar N, Lopes AR, Muratori L, Lenzi M, Bianchi FB, Mieli-Vergani G, Vergani D. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule. J Immunol 2002; 169: 277-285.
135. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006; 130: 868-882.
136. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 1370-1378.
137. Masaki R, Yamamoto A, Tashiro Y. Cytochrome P450 and NADPH-cytochrome P450 reductase are degraded in the autolysosomes in rat liver. J Cell Biol 1987; 104: 1207-1215.
138. Masubuchi Y, Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 1999; 12: 1028-1032.
139. Masuyama H, Inoshita H, Hiramatsu Y, Kudo T. Ligands have various potential effects on the degradation of pregnane X receptor by proteasome. Endocrinology 2002; 143: 55-61.
140. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28: 1031-1037.
141. Meyer HH, Shorter JG, Seemann J, Pappin D, Warren G. A complex of mammalian ufd1 and npl4 links the AAA-ATPase, p97, to ubiquitin and nuclear transport pathways. EMBO J 2000; 19: 2181-2192.
142. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM. Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci USA 1994; 91: 12740-12744.
143. Mizushima N. The pleiotropic role of autophagy: from protein metabolism to bactericide. Cell Death Differ 2005; 12 (Suppl 2 ): 1535-1541.
144. Mizushima N, Klionsky DJ. Protein turnover via autophagy: implications for metabolism. Annu Rev Nutr 2007; 27: 19-40.
145. Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, Kuno N, Osaka T. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 2005; 37: 235-252.
146. Moreau A, Vilarem MJ, Maurel P, Pascussi JM. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol Pharm 2008; 5: 35-41.
147. Morgan ET, Goralski KB, Piquette-Mille, M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205-216.
148. Morishima Y, Peng HM, Lin HL, Hollenberg PF, Sunahara RK, Osawa Y, Pratt WB. Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent stabilization and CHIP-dependent proteasomal degradation. Biochemistry 2005; 44: 16333-16340.
149. Murata S, Chiba T, Tanaka K. CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 2003; 35: 572-578.
150. Murray BP, Correia MA. Ubiquitin-dependent 26S proteasomal pathway: A role in the degradation of the native human liver CYP3A4 expressed in Saccharomyces cerevisiae ? Arch Biochem Biophys 2001; 393: 106-116.
151. Murray BP, Zgoda VG, Correia MA. Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the ubiquitin-26S proteasome system in the degradation of this endoplasmic reticulum enzyme. Mol Pharmacol 2002; 61: 1146-1153.
152. Nakajima M, Yoshida R, Shimada N, Yamazaki H, Yokoi T. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate. Drug Metab Dispos 2001; 29: 1110-1113.
153. Omura T, Siekevitz P, Palade GE. Turnover of constituents of the endoplasmic reticulum membranes of rat hepatocytes. J Biol Chem 1967; 242: 2389-2239.
154. Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys 2009; 483: 66-74.
155. Paine MF, Oberlies NH. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin Drug Metab Toxicol 2007; 3: 67-80.
156. Parkinson A, Thomas PE, Ryan DE, Levin W. Differential time course of induction of rat liver microsomal cytochrome P-450 isozymes and epoxide hydrolase by Aroclor 1254. Arch Biochem Biophys 1983; 225: 203-215.
157. Passmore LA. The anaphase-promoting complex (APC): the sum of its parts? Biochem Soc Trans 2004; 32: 724-727.
158. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112.
159. Peng J. Evaluation of proteomic strategies for analyzing ubiquitinated proteins. BMB Rep 2008; 41: 177-183.
160. Pessayre D. Toxic and immune mechanisms leading to acute and subacute drug induced liver injury. In: Miguet JP, Dhumeaux D, editors. Progress in Hepatology. Paris: John Libbey Eurotext, 1993, pp. 23-39.
161. Peters JM, Harris JR, Finley D, editors. Ubiquitin and the Biology of the Cell. New York: Plenum Press, 1998.
162. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 503-533.
163. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004; 5: 177-187.
164. Pinto AG, Horlander J, Chalasani N, Hamman M, Asghar A, Kolwankar D, Hall SD. Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein. Br J Clin Pharmacol 2005; 59: 440-446.
165. Pitlick WH, Levy RH, Tropin AS, Green JR. Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 1976; 65: 462-463.
166. Raasi S, Wolf DH. Ubiquitin receptors and ERAD: a network of pathways to the proteasome. Semin Cell Dev Biol 2007; 18: 780-791.
167. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9: 679-690.
168. Ravid T, Kreft SG, Hochstrasser M. Membrane and soluble substrates of the Doa10 ubiquitin ligase are degraded by distinct pathways. EMBO J 2006; 25: 533-543.
169. Risseeuw EP, Daskalchuk TE, Banks TW, Liu E, Cotelesage J, Hellmann H, Estelle M, Somers DE, Crosby WL. Protein interaction analysis of SCF ubiquitin E3 ligase subunits from Arabidopsis. Plant J 2003; 34: 753-767.
170. Roberts BJ. Evidence of proteasome-mediated cytochrome P450 degradation. J Biol Chem 1997; 272: 9771-9778.
171. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. J Biol Chem 1995; 270: 29632-29635.
172. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonierbale E, Dansette P, Ballet F, Mansuy D, Pessayre D. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 1996; 98: 1471-1480.
173. Robin MA, Descatoire V, Le Roy M, Berson A, Lebreton FP, Maratrat M, Ballet F, Loeper J, Pessayre D. Vesicular transport of newly synthesized cytochromes P4501A to the outside of rat hepatocyte plasma membranes. J Pharmacol Exp Ther 2000; 294: 1063-1069.
174. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC. Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006; 7: 441-448.
175. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771.
176. Ronis MJ, Ingelman-Sundberg M. Acetone-dependent regulation of cytochrome P450j (IIE1) and P450b (IIB1) in rat liver. Xenobiotica 1989; 19: 1161-1165.
177. Ronis MJ, Johansson I, Hultenby K, Lagercrantz J, Glaumann H, Ingelman-Sundberg M. Acetone-regulated synthesis and degradation of cytochrome P450E1 and cytochrome P4502B1 in rat liver. Eur J Biochem 1991; 198: 383-389.
178. Russo A, Fratto ME, Bazan V, Schiró V, Agnese V, Cicero G, Vincenzi B, Tonini G, Santini D. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. Expert Opin Ther Targets 2007; 11: 1571-1586.
179. Schafer A, Wolf DH. Endoplasmic reticulum-associated protein quality control and degradation: screen for ERAD mutants after ethylmethane sulfonate mutagenesis. Methods Mol Biol 2005; 301: 283-288.
180. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-1233.
181. Seglen PO. Regulation of autophagic protein degradation in isolated liver cells. In: Glaumann H, Ballard FJ, editors. Lysosomes: Their Role in Protein Breakdown. London: Academic Press, 1987, pp. 371-414.
182. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004; 306: 990-995.
183. Shiraki H, Guengerich FP. Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P-450 reductase and epoxide hydrolase. Arch Biochem Biophys 1984; 235: 86-96.
184. Shringarpure R, Grune T, Davies KJA. Protein oxidation and 20S proteasome dependent proteolysis in mammalian cells. Cell Mol Life Sci 2001; 58: 1442-1450.
185. Silverman RB. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, Vol. 1. Boca Raton, fl: CRC Press, 1988, pp. 3-30.
186. Sokolik CW, Cohen RE. Ubiquitin conjugation to cytochromes c. Structure of the yeast iso-1 conjugate and possible recognition determinants. J Biol Chem 1992; 267: 1067-1071.
187. Song BJ, Veech RL, Park SS, Gelboin HV, Gonzalez FJ. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 1989; 264: 3568-3572.
188. Steinberg RA, Levinson BB, Tomkins GM. Kinetics of steroid induction and deinduction of tyrosine aminotransferase synthesis in cultured hepatoma cells. Proc Natl Acad Sci USA 1975; 72: 2007-2011.
189. Steward AR, Wrighton SA, Pasco DS, Fagan JB, Li D, Guzelian PS. Synthesis and degradation of 3-methylcholanthrene-inducible cytochromes P-450 and their mRNAs in primary monolayer cultures of adult rat hepatocytes. Arch Biochem Biophys 1985; 241: 494-508.
190. Swanson R, Locher M, Hochstrasser M. A conserved ubiquitin ligase of the nuclear envelope/endoplasmic reticulum that functions in both ER-associated and Matalpha2 repressor degradation. Genes Dev 2001; 15: 2660-2674.
191. Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008; 9: 826-838.
192. Teckman JH, Perlmutter DH. Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am J Physiol Gastrointest Liver Physiol 2000; 279 :G 961-G 974.
193. Thompson SJ, Loftus LT, Ashley MD, Meller R. Ubiquitin-proteasome system as a modulator of cell fate. Curr Opin Pharmacol 2008; 8: 90-95.
194. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 2006; 114: 1655-1661.
195. Tierney DJ, Haas AL, Koop DR. Degradation of cytochrome P450 2E1: Selective loss after labilization of the enzyme. Arch Biochem Biophys 1992; 29: 9-16.
196. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, Schuetz EG, Kim RB. The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9: 220-224.
197. Tsuji H, Akasaki K. Identification and characterization of lysosomal enzymes involved in the proteolysis of phenobarbital-inducible cytochrome P450. Biol Pharm Bull 1994; 17: 568-571.
198. Ueno T, Muno D, Kominami E. Membrane markers of endoplasmic reticulum preserved in autophagic vacuolar membranes isolated from leupeptin-administered rat liver. J Biol Chem 1991; 266: 18995-18999.
199. Uetrecht J. Current trends in drug-induced autoimmunity. Autoimmun Rev 2005; 4: 309-314.
200. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-539.
201. Uibo R, Aavik E, Peterson P, Perheentupa J, Aranko S, Pelkonen R, Krohn KJ. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison's disease. J Clin Endocrinol Metab 1994; 78: 23-28.
202. van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA. Bosentan, a dual endothelin receptor antagonist activates the pregnane X nuclear receptor. Eur J Pharmacol 2002; 450: 115-121.
203. Varshavsky A. Naming a targeting signal. Cell 1991; 64: 13-15.
204. Varshavsky A. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci USA 1996; 93: 12142-12149.
205. Vidali M, Hidestrand M, Eliasson E, Mottaran E, Reale E, Rolla R, Occhino G, Albano E, Ingelman-Sundberg M. Use of molecular simulation for mapping conformational CYP2E1 epitopes. J Biol Chem 2004; 279: 50949-50955.
206. Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003; 42: 1331-1357.
207. a degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch Biochem Biophys 1999; 365: 45-53.
208. Wang X, Medzihradszky KF, Maltby D, Correia MA. Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric characterization of the phosphorylated peptides. Biochemistry 2001; 40: 11318-11326.
209. Wang Y, Liao M, Hoe N, Acharya P, Deng C, Krutchinsky AN, Correia MA. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem 2009; 284: 5671-5684.
210. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitinproteasome pathway. Cell 1995; 83: 121-127.
211. Watkins PB, Wrighton SA, Schuetz EG, Maurel P, Guzelian PS. Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. J Biol Chem 1986; 261: 6264-6271.
212. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
213. Watson G, Davey RA, Labarca C, Paigen K. Genetic determination of kinetic parameters in beta-glucuronidase induction by androgen. J Biol Chem 1981; 256: 3005-3011.
214. Weissman A. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2001; 2: 169-178.
215. Whiteside S, Ernst M, LeBail O, Laurent-Winter C, Rice N, Israel A. N-and C-terminal sequences control degradation of MAD3/I kappa B alpha in response to inducers of NF-kappa B activity. Mol Cell Biol 1995; 15: 5339-5345.
216. Wilkinson KD. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997; 11: 1245-1256.
217. Wolf DH. From lysosome to proteasome: the power of yeast in the dissection of proteinase function in cellular regulation and waste disposal. Cell Mol Life Sci 2004; 61: 1601-1604.
218. Yamamoto A, Masaki R, Tashiro Y. Is cytochrome P-450 transported from the endoplasmic reticulum to the Golgi apparatus in rat hepatocytes? J Cell Biol 1985; 101: 1733-1740.
219. Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 1105-1111.
220. Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384-394.
221. Yang MX, Cederbaum AI. Role of the proteasome complex in degradation of human CYP2E1 in transfected HepG2 cells. Biochem Biophys Res Commun 1996; 226: 711-716.
222. Yang MX, Cederbaum AI. Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. Arch Biochem Biophys 1997; 341: 25-33.
223. Yewdell JW. Immunoproteasomes: regulating the regulator. Proc Natl Acad Sci USA 2005; 102: 9089-9090.
224. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ 2005; 12 (Suppl 2 ): 1542-1552.
225. Zangar RC, Kimzey AL, Okita JR, Wunschel DS, Edwards RJ, Kim H, Okita R. Cytochrome P450 3A conjugation to ubiquitin in a process distinct from classical ubiquitination pathway. Mol Pharmacol 2002; 61: 892-904.
226. Zhang DD. Mechanistic studies of the Nrf2-Keap1 pathway. Drug Metab Rev 2006; 38: 769-789.
227. Zhang QX, Melnikov Z, Feierman DE. Characterization of the acetaminophen-induced degradation of cytochrome P450-3A4 and the proteolytic pathway. Basic Clin Pharmacol Toxicol 2004; 94: 191-200.
228. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St John's wort. Curr Drug Metab 2008; 9: 394-409.
229. Zhukov A, Ingelman-Sundberg M. Selective fast degradation of cytochrome P450 2E1 in serum-deprived hepatoma cells by a mechanism sensitive to inhibitors of vesicular transport. Eur J Biochem 1997; 247: 37-43.
230. Zhukov A, Ingelman-Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem J 1999; 340: 453-458.
231. Zhukov A, Werlinder V, Ingelman-Sundberg M. Purification and characterization of two membrane bound serine proteinases from rat liver microsomes active in degradation of cytochrome P450. Biochem Biophys Res Commun 1993; 197: 221-228.